FIELD: organic chemistry, chemical technology, medicine, pharmacy.
SUBSTANCE: invention relates to pharmaceutically acceptable salts of compound of the formula (I)
or solvates of indicated salt wherein compound of the formula (I) is represented as (R)-enantiomer, (S)-enantiomer or racemate. Invention describes a pharmaceutically acceptable salt of compound of the formula (I) or solvate of indicated salt wherein compound of the formula (I) is represented as (R)-enantiomer, (S)-enantiomer or racemate under condition that (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamidehydro-(2S,3S)-tartrate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamidehydro-(2R,3R)-tartrate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide benzene sulfonate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamidehydro-1,2-ethane disulfonate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide hydromaleate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide hydrosulfate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide D-gluconate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide hydrosuccinate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide methane sulfonate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamidehydro-(S)-maleate, (R)-N-[5-methyl-8-(4-methylpipearzine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide dihydrocitrate and (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenamide hydrochloride are excluded. Also, invention describes a pharmaceutical composition based on salts and/or solvates by cl. 1-9 eliciting the selective effect on 5-hydroxytryptamine receptor subgroup, method for treatment based on using salts and/or solvates by cl. 1-9, and a method for preparing salt of solvate of compound of the formula (I). Invention provides preparing new salts and solvates of biologically active compounds.
EFFECT: improved preparing method, valuable medicinal properties of compound and composition.
31 cl, 1 dwg, 18 ex
Title | Year | Author | Number |
---|---|---|---|
DERIVATIVES OF 1,2,3,4-TETRAHYDRONAPHTHALENE, METHODS OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD OF TREATMENT | 1998 |
|
RU2194696C2 |
COMBINATION OF SELECTIVE ANTAGONIST OF 5HT AND SELECTIVE ANTAGONIST OR PARTIAL AGONIST OF H5-HT | 1998 |
|
RU2215528C2 |
COMBINATION OF INHIBITOR OF 5-HT REUPTAKE AND ANTAGONIST OR PARTIAL AGONIST H5-HT | 1998 |
|
RU2214824C2 |
TETRALINE AND INDANE DERIVATIVES AND USE THEREOF | 2005 |
|
RU2389723C2 |
TETRALIN AND INDANE DERIVATIVES AND USE THEREOF AS 5-HT ANTAGONISTS | 2005 |
|
RU2388748C2 |
DERIVATIVES OF AZOLE AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF ELICITING ACTIVITY WITH RESPECT TO SEROTONIN 5-HT- | 1995 |
|
RU2146256C1 |
DERIVATIVES OF AMIDES AND UREA AS INHIBITORS OF REUPTAKE OF 5-HT AND LIGANDS OF 5-HT1B/1D | 1998 |
|
RU2211216C2 |
METHOD OF SYNTHESIS OF 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE ACID-ADDITIVE SALT | 1989 |
|
RU2014330C1 |
COMPOUNDS | 2003 |
|
RU2327690C2 |
NOVEL ARYLALKYLINDOLES SHOWING AFFINITY TO SEROTONIN RECEPTOR AND USEFUL AS DRUGS, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF | 2003 |
|
RU2320663C2 |
Authors
Dates
2004-10-10—Published
2000-01-14—Filed